Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial
February 10 2022 - 1:00AM
Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1
Clinical Trial
PRESS RELEASE
February 10,
2022
Saniona (OMX: SANION), a clinical stage
biopharmaceutical company focused on rare diseases, today
provided an update on progress in its
Phase 1 clinical trial
of SAN711. The company reported that it
has now also initiated the
multiple ascending dose stage of the
trial. The study is
placebo-controlled, and the data remain blinded.
Saniona continues to expect data from the
trial by the end
of the first half
of 2022.
“We are encouraged to have enrolled and dosed participants in
multiple cohorts of the single ascending dose stage of the SAN711
Phase 1 clinical trial and to have now also initiated the multiple
ascending dose stage,” said Rudolf Baumgartner, M.D., Chief Medical
Officer and Head of Clinical Development at Saniona. “We continue
to expect topline data from this study by the end of the first half
of this year.”
The Phase 1 clinical trial is a randomized, placebo-controlled
study being conducted in approximately 80 healthy volunteers. The
primary objective of the study is to determine the tolerability and
the maximum tolerated dose of SAN711, as evaluated through the
single ascending dose and multiple ascending dose phases of the
study. The secondary objective is to measure binding to target
receptors, as assessed during a positron emission tomography (PET)
evaluation phase of the study. More information is available at
www.clinicaltrials.gov.
SAN711 is an investigational, potential first-in-class positive
allosteric modulator of GABA-A α3 receptors and may be applicable
in the treatment of rare neuropathic disorders. It is the first
novel molecule derived from Saniona’s proprietary ion channel drug
discovery engine to be advanced into internal clinical trials.
For more information, please contact Trista
Morrison, Chief Communications Officer, Saniona. Office: + 1 (781)
810-9227. Email: trista.morrison@saniona.com
The information was submitted for publication, through the
agency of the contact person set out above, at 8:00 CET on 10
February 2022.
About Saniona Saniona is a clinical-stage
biopharmaceutical company focused on discovering, developing and
commercializing innovative therapies for patients suffering from
rare diseases for which there are a lack of available treatment
options. The company’s lead product candidate, Tesomet™, is in
mid-stage clinical trials for hypothalamic obesity and Prader-Willi
syndrome, serious rare disorders characterized by severe weight
gain, disturbances of metabolic functions and uncontrollable
hunger. Saniona has developed a proprietary ion channel drug
discovery engine anchored by IONBASE™, a database of more than
130,000 compounds, of which more than 20,000 are Saniona’s
proprietary ion channel modulators. Through its ion channel
expertise, Saniona is advancing two wholly-owned ion channel
modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical
trial and may be applicable in the treatment of rare neuropathic
disorders, and SAN903 is in preclinical development for rare
inflammatory, fibrotic and hematological disorders. Led by an
experienced scientific and operational team, Saniona has an
established research organization in the Copenhagen area, Denmark,
and a corporate office in the Boston, Massachusetts area, U.S. The
company’s shares are listed on Nasdaq Stockholm Small Cap (OMX:
SANION). Read more at http://www.saniona.com.
- SAN711 Update Press Release_02.10.22
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Jan 2025 to Feb 2025
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Feb 2024 to Feb 2025
